Prescrire Int. 2015 Sep;24(163):220.
Two randomised trials have compared 5 years versus 10 years of tamoxifen therapy following surgery for hormone receptor-positive early breast cancer. Overall mortality, breast cancer-related mortality and the breast cancer recurrence rate were all lower when tamoxifen was continued for 10 years. Prolonging tamoxifen therapy increased the incidence of endometrial cancer and thromboembolic events. The value of tamoxifen therapy therefore decreases over time.
两项随机试验比较了激素受体阳性早期乳腺癌手术后他莫昔芬治疗5年与10年的效果。他莫昔芬持续治疗10年时，总死亡率、乳腺癌相关死亡率和乳腺癌复发率均较低。延长他莫昔芬治疗会增加子宫内膜癌和血栓栓塞事件的发生率。因此，他莫昔芬治疗的价值会随着时间降低。
